Sanofi-Aventis (NYSE: SNY) unveiled a further push into emerging markets with plans to buy Polish consumer healthcare group Nepentes in a deal valuing it at around 105 million euros ($130.4 million). Release | Report
For innovative pharmaceutical companies, opportunities for new pharmaceutical products exist within the products, patents, technologies and intellectual properties they already own or control. For these companies, and also for generic companies that are looking for alternative revenue sources to offset losses caused by the generic cliff, the 505(b)(2) pathway offers great potential. Learn more here.
FiercePharma is the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Join 100,000+ pharma industry leaders who get FiercePharma via daily email. Click here to get your free weekly email briefing today!